Holen Sie sich die Stockscreener-App
2.92
2.68%
-0.07
Schlusskurs vom Vortag:
$2.99
Offen:
$2.96
24-Stunden-Volumen:
11,404
Relative Volume:
0.01
Marktkapitalisierung:
$336.18M
Einnahmen:
$618.00K
Nettoeinkommen (Verlust:
$-111.65M
KGV:
-2.0917
EPS:
-1.396
Netto-Cashflow:
$-107.53M
1W Leistung:
-6.73%
1M Leistung:
-3.00%
6M Leistung:
-45.61%
1J Leistung:
-9.91%
1-Tages-Spanne:
$2.945
$3.01
1-Wochen-Bereich:
$2.945
$3.18
52-Wochen-Spanne:
$1.955
$6.16
Perspective Therapeutics Inc Stock (CATX) Company Profile
Firmenname
Perspective Therapeutics Inc
Sektor
Branche
Telefon
509-375-1202
Adresse
350 Hills Street, Suite 106, Richland
Compare CATX vs ABT, MDT, SYK, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CATX
Perspective Therapeutics Inc
|
2.945 | 356.15M | 618.00K | -111.65M | -107.53M | -1.396 |
ABT
Abbott Laboratories
|
104.70 | 182.09B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
91.02 | 117.54B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
271.87 | 105.63B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
44.06 | 65.16B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.01 | 49.67B | 6.30B | 1.07B | 1.09B | 1.8406 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-10-10 | Eingeleitet | BTIG Research | Buy |
| 2025-03-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-11-25 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-10-01 | Eingeleitet | Wedbush | Outperform |
| 2024-09-25 | Eingeleitet | Truist | Buy |
| 2024-07-25 | Eingeleitet | BofA Securities | Buy |
| 2024-05-09 | Eingeleitet | Cantor Fitzgerald | Overweight |
Alle ansehen
Perspective Therapeutics Inc Aktie (CATX) Neueste Nachrichten
Perspective Therapeutics (CATX) Insider Sale: 10% Owner Lantheus Alpha Therapy, LLC Sells 247,932 Shares - GuruFocus
Perspective Therapeutics updates corporate presentation highlighting 212Pb pipeline, $45B addressable market - TradingView
Perspective Therapeutics (CATX) highlights 3 cancer drug programs - Stock Titan
Perspective Therapeutics (CATX) holder sells stock near $3.10 - Stock Titan
Lantheus Alpha Therapy Sells 113,914 Perspective Therapeutics (AMEX: CATX) Shares at Up to $3.14 Per Share - Kalkine Media
Lantheus Group Reduces Stake in Perspective Therapeutics (AMEX: CATX) to 10% Amid Activist 13D Filing - Kalkine Media
Lantheus Holdings (NASDAQ: LNTH) 10% Stakeholder Alpha Therapy Sells 42,129 Shares at $3.11 Each - Kalkine Media
Perspective Therapeutics (CATX) Insider Sell: 10% Owner Lantheus Alpha Therapy, LLC Disposes of 42,129 Shares - GuruFocus
Lantheus Holdings (NASDAQ: LNTH) Disposes of 35,769 Perspective Therapeutics Shares at $3.12 Each - Kalkine Media
Perspective Therapeutics (CATX) backer trims stake but keeps 11.5M shares - Stock Titan
10% owner of Perspective Therapeutics (NYSE: CATX) sells 113,914 shares over two days - Stock Titan
Perspective Therapeutics (CATX) backer Lantheus now owns 10% after share sales - Stock Titan
Perspective Therapeutics Inc (CATX) Insider Sell: 10% Owner Holdings, Lantheus Disposes of 35,769 Shares - GuruFocus
Perspective Therapeutics (CATX) holder sells 35K shares, still owns 11.6M - Stock Titan
Perspective Therapeutics Inc (CATX) Insider Sell: 10% Owner Holdings, Lantheus Disposes of 78,145 Shares - GuruFocus
Lantheus Holdings sells $245,609 in Perspective Therapeutics stock By Investing.com - Investing.com Nigeria
Lantheus Holdings sells $245,609 in Perspective Therapeutics stock - Investing.com
Perspective Therapeutics: 'Strong Buy' On Bamzireotide Navoxetan Reinforced Data And Phase 3 Plans - Seeking Alpha
Perspective Therapeutics (CATX) Slides 3.19% as $3.03 Support Comes into FocusMomentum Surge Alerts - vinanet.vn
Perspective Therapeutics (CATX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - easternprogress.com
BMO Capital Markets Upgrades Perspective Therapeutics (NYSEAMERICAN:CATX) to "Strong-Buy" - MarketBeat
Perspective (CATX) Range: Posts a 8.41% Gain to $3.48 for the Current Session; Chart View - vinanet.vn
PERSPECTIVE THERAPEUTICS INC : BMO INITIATES COVERAGE WITH OUTPERFORM RATING; PRICE TARGET $11 - Bitget
Perspective Therapeutics Market Sentiment - Benzinga France
CATX Initiated by BMO Capital -- Rating Set to Outperform - GuruFocus
Perspective Therapeutics Price Target Announced at $11.00/Share by BMO Capital - Moomoo
BMO initiates Perspective Therapeutics stock at Outperform, $11 target By Investing.com - Investing.com South Africa
BMO initiates Perspective Therapeutics stock at Outperform, $11 target - Investing.com
BMO Capital Initiates Perspective Therapeutics at Outperform - marketscreener.com
BMO Capital Initiates Coverage on CATX with Outperform Rating, H - GuruFocus
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
CATX Q1 2026 Earnings: Loss Beats Estimates by 17.25%, Shares Rise 3.23%Revenue Growth Outlook - Vinanet
CATX Maintained by B of A Securities -- Price Target Lowered to $5.00 - GuruFocus
Bank of America Lowers Perspective Therapeutics (NYSEAMERICAN:CATX) Price Target to $5.00 - MarketBeat
BofA Securities Maintains Perspective Therapeutics(CATX.US) With Hold Rating, Cuts Target Price to $5 - Moomoo
Q3 EPS Forecast for Perspective Therapeutics Lifted by Analyst - MarketBeat
BofA Securities Adjusts Perspective Therapeutics Price Target to $5 From $6 - marketscreener.com
Dimensional Fund Advisors LP Acquires 358,540 Shares of Perspective Therapeutics, Inc. $CATX - MarketBeat
Perspective Therapeutics (CATX): Millennium group reports over 5% beneficial stake - Stock Titan
Analysts Set Expectations for Perspective Therapeutics Q1 Earnings - MarketBeat
RBC Capital Sticks to Their Buy Rating for Perspective Therapeutics (CATX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Atossa Therapeutics (ATOS), Corvus Pharmaceuticals (CRVS) and Perspective Therapeutics (CATX) - The Globe and Mail
Perspective Therapeutics, Inc. (CATX) Latest Stock News & Headlines - Yahoo Finance
Perspective Therapeutics (CATX) Gets a Buy from Oppenheimer - The Globe and Mail
Piper Sandler cuts Perspective Therapeutics price target on timing By Investing.com - Investing.com Australia
Perspective Therapeutics's NET Program Data May Allow Phase 3 Trial Start, Value Inflection, RBC Says - marketscreener.com
Piper Sandler cuts Perspective Therapeutics price target on timing - Investing.com
CATX Maintained by Piper Sandler -- Price Target Lowered to $14. - GuruFocus
Perspective Therapeutics (NYSEAMERICAN:CATX) Price Target Lowered to $14.00 at Piper Sandler - MarketBeat
Perspective Therapeutics Price Target Cut to $14.00/Share From $16.00 by Piper Sandler - Moomoo
Perspective Therapeutics (CATX) Climbs 4.7% to $3.14 as Buyers Defend Key SupportSmart Beta Flow - dars.gov.et
Finanzdaten der Perspective Therapeutics Inc-Aktie (CATX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
1.96%
Kapitalisierung:
|
Volumen (24h):